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the acceptance and commissioning of medical radiological equipment, 
need to be fulfilled by or under the oversightof or with the 
documented advice of a medical physicist. The degree of involvement 
of the medical physicist in diagnostic uses and image-guided 
interventional procedures is determined by the complexity of the 
radiological procedures and the associated radiation risks.  
In conclusion, the new BSS identifies the medical physicist as a key 
professional with a specialized training, skills and competence in 
clinical medical physics and radiation protection. The medical 
physicist has significant responsibilities in the many activities that are 
needed to successfully implement the quality assurance programme 
and radiation protection principle of optimization for medical 
exposure in a given hospital or medical centre. If these new BSS 
requirements are effectively implemented, they will help pave the 
way for a full recognition of the medical physicist as a health care 
professional alongside other professionals working in the medical 
field. 
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Purpose/Objective:  Imaging for patient positioning is part of the 
image guided radiation therapy (IGRT) workflow and is routinely used 
in clinical practice. The primary objective is to check and correct the 
patient position with such an improved day to day reproducibility that 
dose delivery to the target volume and organs at risks is the most 
similar to the planned one. This can be accomplished by plenty of 
imaging techniques based on kV, MV or ultrasound imaging and made 
available by companies in various mechanical configurations. The 
objective of this teaching lecture is to provide an overview of the 
different techniques used and to evaluate their respective pros and 
cons. 
Materials/Methods: A review of literature is presented from the 
simplest two dimensional imaging techniques to the most advanced 
ones capable of imaging the movement of the patient in four 
dimensions (4D). Special focus is presented on high precision 
irradiation techniques such as stereotactic radiosurgery, where 
treatment outcome is the most dependent on accurate patient 
positioning.  
Results: Globally, the performance of the most advanced imaging 
techniques allows us to position the patient and the target volume 
within millimeters and even under 1 mm for parts of the body which 
can be rigidly immobilized. Also taking into account target volume 
movements with 4D imaging techniques prior to treatment, e.g. for 
lung treatments, allow us to reduce the irradiated volume and 
therefore potentially reduce toxicity. The great improvement of 
imaging techniques in recent years raises then the question of the 
interest of frameless high precision irradiation techniques, because 
these techniques, based on imaging without invasive frame 
contention, are definitely providing equivalent degree of accuracy in 
patient positioning.  
Conclusions: IGRT techniques for patient positioning are widespread 
in clinical practice. Recent improvements allow us to position the 
patient and the target volume within 1mm accuracy. Most advanced 
techniques even take into account target movement by 4D imaging of 
patient positioning. Stereotactic high precision irradiation based on 
frameless imaging also challenges the usual invasive frame-based 
technique for patient positioning precision. 
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The strength of brachytherapy (BT) is that the radiation sources are 
inside or in the vicinity of the target volume and that they generally 
move with the target. The target dose is high and due to the inverse 
square law the dose to the surrounding normal tissue (organs at risk) 
can be reduced considerably. Therefore, BT has gained a definite 
place in the treatment of patients with gynaecological, head and 
neck, breast and prostate tumours.  
Brachytherapy has been applied since 1901, a few years after the 
discovery of x-rays and radium. Important developments in the 
medical application of radionuclides were the dosimetry systems 
(Stockholm, Paris, Manchester), the discovery of artificial 
radioactivity ( 60Co,137Cs, 198Au, 192Ir) and the development of 
remote afterloading devices. 
The field of BT continues to develop and the introduction of new 
technology brings new questions and challenges [1]: 
new afterloading devices, new dose calculation algorithms, 3D image 
based dose planning, new applicators,  application of knowledge of 
radiobiology to optimize treatment schedules, robotic brachytherapy 
for prostate seed implant, electronic brachytherapy sources and in 
vivo dosimetry. 
 A major improvement of BT may be expected from the use of 3D 
imaging, especially magnetic resonance imaging (MRI).  MRI does not 
completely replace clinical investigation and other imaging 
modalities, but its superior soft tissue contrast often helps to better 
define tumor stage, target volume extension and organs at risk at 
time of diagnosis, at time of BT and for treatmentplanning purposes.  
During the last years we see a development towards MR guided BT in 
different tumor sites(gynaecology, prostate). This presentation will 
focus on technology for MRI guided BT and how anatomical and 
functional MRI optimize and individualize BT approaches. 
1. Venselaar JL, Baltas D, Meigooni AS, Hoskin PJ (editors), 
Comprehensive Brachytherapy; Physical and Clinical Aspects, CRC 
Press, 2012. 
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Superficial esophageal cancer (SEC) is defined as esophageal cancer 
limited to the submucosal layer and includes mucosal and submucosal 
cancer. Based on the criteria of the Japanese Society for Esophageal 
Disease, Mucosal and submucosal cancer is classified according to 
location: epithelial layer (m1); proper mucosal layer (m2); muscularis 
mucosa (m3); upper third of the submucosal level (sm1); middle third 
of the submucosal layer (sm2); and the lower third of the submucosal 
level (sm3). Irrespective of the treatment method, the depth of 
invasion is one of the most important prognostic factors of SEC 
because lymph node metastasis markedly increases in lesions 
infiltrating the lamina muscularis mucosa (m3).  
The best management of small m1 and m2 esophageal cancer is 
generally endoscopic resection (ER). For m3-sm3 SEC, extensive lymph 
node dissection has been the most popular choice of 
treatment.However, after introduction of chemoradiation therapy, 
good treatment outcomes which are comparable with those of surgery 
have been reported. In a Japanese phase II study of CRT for T1 
esophageal carcinoma (JCOG 9704), 4 and 5 year overall survival rates 
were 80.5% and 76.5%, respectively. In our prospective single 
institutional phase II study, local control rate, and overall survival 
rate was 80.3%, % 78.9and % respectively. From these data, we think 
CRT for early state esophageal carcinoma is one of the standard 
treatment methods.  
Combination of ER and CRT is another approach. If the depth of 
invasion reached to submucosa, surgery has been added to most 
patients because of the high rate of lymph node metastasis. However, 
treatment outcomes of post ER CRT to prevent lymph node recurrence 
seems to be excellent and this approach may become a standard 
treatment method for endoscopically resectable esophageal cancer.  
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Early-stage esophageal cancer can be defined as locally resectable 
disease ((1) Ever since, several important developments (including 
Barrett surveillance, improvement of clinical staging by e.g. PET 
scanning, centralization of care, refined perioperative therapy, and 
more radical surgical techniques) have improved short-term and long-
term outcome. However, 5-year survival after potentially curative 
surgical resection still rarely exceeds 35%. 
Many clinical trials have tested the potential value of neoadjuvant 
chemo- and/or radiotherapy to improve long-term outcome. In five 
randomized controlled trials (RCTs) the efficacy of neoadjuvant 
radiotherapy has been tested. A meta-analysis showed a non-
significant 4% increase of 5 year survival rate.(2) Nine RCTs have been 
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performed to test the role of neoadjuvant chemotherapy. Some of 
these trials showed contradictory results (esp. Kelsen-RTOG(3) versus 
Allum/Clark-MRC(4)), but the overall 5-year survival advantage with 
neoadjuvant chemotherapy is probably <5%.(5) In most RCTs 
comparing neoadjuvant chemoradiotherapy followed by surgery versus 
surgery alone no significant benefit for the combined modality arm 
could be demonstrated. However, most of these (older) trials did not 
meet today’s standard of care and were generally underpowered. In 
the meta-analysis a survival benefit was suggested with the use of 
preoperative chemoradiotherapy.(6) 
Recently, we published the results of a multicenter Dutch RCT, 
comparing chemoradiotherapy (5 courses of weekly paclitaxel/ 
carboplatin and concurrent radiotherapy, 23x 1.8 Gy) followed by 
surgery versus surgery alone.(7) In general, toxicity was mild. In-
hospital mortality was comparable (4% in both groups) and no 
difference in postoperative morbidity was observed. The R0-radical 
resection rate was higher in the multimodality arm (92% vs. 69%). 
Median overall survival was superior in the multimodality arm (49% vs 
24%), while 5-year overall survival was 47% in the multimodality arm 
versus 34% in the surgery alone arm (p=0.003). Therefore, we now 
consider neoadjuvant chemoradiotherapy plus radical surgical 
resection as standard treatment for patients with potentially curable 
(cT1b-N1M0, cT2-4aNxM0) esophageal cancer. 
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In this short lecture, recent progress in radiation therapy (RT) for 
locally advanced esophageal cancer in Japan will be presented.  At 
present, concurrent chemotherapy (CT) of 5-FU/cisplatin combined 
with RT is a standard chemo-radiotherapy (CRT) regimen for locally 
advanced esophageal cancer.  Although full dose 5-FU/cisplatin is 
combined with RT in the USA, several Japanese investigators showed 
promising clinical results using low dose protracted infusion CT 
combined with full dose RT of 60-66 Gy for locally advanced 
esophageal squamous cell carcinomas.  Low dose protracted infusion 
of 5-FU or 5-FU plus cisplatin were proposed to reduce the acute 
toxicities due to concurrent CRT.  In addition, to obtain maximum 
radio-sensitization by CT, daily administration of low dose protracted 
CT combined with RT may be better than full dose short-term CT plus 
RT.  To test the above hypothesis, a randomized phase II study was 
conducted to compare the relative toxicity and efficacy of combining 
full dose short-term CT (arm A) or low dose protracted CT (arm B) 
with RT for esophageal cancer (KROSG0101/JROSG021) (1).  As a final 
analysis, low dose protracted infusion CT with RT is not superior to 
full dose short-term infusion CT with RT for esophageal cancer.  For 
both groups, late toxicities of grade 3 or more were noted 17-18% of 
the patients.  Most of the toxicities were cardiac or pleural toxicities, 
and patients with severe late toxicities often had coexistent 
hypothyroidism.         
To determine the clinical results of CRTfor esophageal cancer in 
Japan, a questionnaire-based survey for esophageal cancer treated by 
definitive RT between 1999 and 2003 was conducted (2).  Clinical 
results of definitive RT for patients were collected from 9 major 
institutions.  Only patients with good performance status (PS0-2) who 
received a total dose of 50 Gy or more were included.  Patients were 
classified into three groups; A) stage I-B) resectable stages II-III-C) 
unresectable stages III-IVA.  For group A, all patients treated by RT 
alone or chemo-radiotherapy (CRT) were included.  For groups B and 
C, only those treated by CRT were included.  The median total RT 
dose ranged from 60 Gy to 66 Gy.  The median and range of the 5-year 
overall survival rates were 56% (48-83%) for group A,29% (12-52%) for 
group B, and 19% (0-31%) for group C, respectively.  A significant 
disparity in survival rates wa snoted among the institutions for stage 
II-IVA tumors treated by CRT.  Interestingly, a significant correlation 
between the number of patients treated per year and the 5-year 
overall survival rate was noted for groups B and C (both p<0.05).  A 
similar volume-outcome relation was demonstrated between the 
number of esophagectomy operations performed per year and the 
operative mortality (3).  Thus, treatment of esophageal cancer should 
be done in limited number of large cancer center hospitals. 
To reduce the late toxicities, improvement in spatial dose distribution 
for esophageal cancer was obtained by conformal RT including 
intensity modulated RT (IMRT).  IMRT is an ideal boost technique for 
locally advanced cervical and upper thoracic esophageal cancers to 
exclude the spinal cord.  We are planning a phase II trial for cervical 
esophageal cancer using IMRT.   
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Radiotherapy in combination with concurrent cisplatin based 
chemotherapy of patients with locally advanced esophageal cancer 
results in 5 year overall survival between 10-30%. In meta-analysis of 
randomized trials comparing surgical treatment with or without 
neoadjuvant chemoradiation to chemoradiation, overall survival was 
identical (Hazard ratio 0.98) for both treatment strategies (1). 
Chemoradiation was associated with a significantly higher locoregional 
recurrence rate (HR:1.54) and a borderline significant lower distant 
metastases rate (HR 0.72; 95%CL 0.52 – 1.01). Treatment related 
mortality was higher with surgical treatment (8.9% vs. 1.3%). The vast 
majority of patients in these trials had squamous cell cancer. The lack 
of a survival benefit for surgery in spite of improved locoregional 
tumor control is mainly a consequence of the relatively high 
treatment related mortality. In randomized trials comparing surgery 
to neodjuvant chemoradiation followed by surgery (2), an increased 
treatment related mortality was reported for patients with squamous 
cell carcinomas, but not for patients with adenocarcinomas. Whether 
this observation is simply the consequence of the less complicated 
surgery of typically distally located adenocarcinomas or is also due to 
lifestyle associated differences in weight and cardiopulmonary 
function, is not well understood. The clinical consequence is that 
patients with locally advanced adenocarcinomas should be treated 
with neoadjuvant treatment followed by surgery, whereas patients 
with squamous cell cancer patients have two options, neoadjuvant 
chemoradiation followed by surgery or primary chemoradiation. Since 
treatment related mortality is higher in patients with impaired 
cardiopulmonary function or poor performance status, primary 
chemoradiation is the preferred treatment, if these conditions are 
present. Tumor location above the carina seems also to be associated 
with a higher risk of perioperative mortality favouring chemoradiation 
for the majority of these patients. Treatment decision based on early 
response to neoadjuvant chemoradiation has also been propagated. 
Patients with responding tumors have a much better clinical outcome 
regardless of whether treatment is completed with surgery of further 
chemoradiation (3), and chemoradiation as the less toxic treatment is 
propagated in case of response. Independent of these considerations, 
new treatment strategies are needed to improve clinical outcome. 
Chemoradiation with total doses between 50 to 65 Gy in combination 
with cisplatin based chemotherapy is standard at the time. The 
addition of taxanes and cetuximab is currently under investigation. 
Improved radiation technology like IMRT and IGRT are also under 
investigation and are expected to lower treatment related toxicity. 
